Karyopharm Therapeutics Inc. filings document the formal disclosures of a commercial-stage oncology company centered on XPOVIO (selinexor), clinical development programs, financing arrangements, and governance matters. Form 8-K reports include operating and financial results, preliminary revenue and liquidity disclosures, clinical and regulatory updates, material agreements, and capital-structure events.
The company’s SEC record also includes proxy materials for annual and special stockholder meetings, director elections, executive compensation, shareholder voting matters, and amendments to authorized share capacity. Additional filings describe private placements, common stock and warrant structures, sales under equity offering arrangements, and amendments to credit and guaranty agreements, including covenant and liquidity terms.
Karyopharm Therapeutics Inc. reported that its President and CEO, Richard A. Paulson, received an award of 81,060 shares of common stock in the form of restricted stock units (RSUs) on February 5, 2026. The RSUs were granted at $0 per share under the company’s 2022 Equity Incentive Plan and increase his directly held beneficial ownership to 279,391 shares of common stock.
The RSUs convert into common stock on a one-for-one basis. Vesting is scheduled so that 50% of the RSUs vest on January 31, 2027, with the remaining 50% vesting on January 31, 2028, tying a portion of the CEO’s compensation to the company’s long-term performance and continued service.
Karyopharm Therapeutics executive Lori Macomber reported an automatic tax-related stock sale. On 02/03/2026, the EVP, CFO & Treasurer sold 1,626 shares of Karyopharm Therapeutics Inc. common stock at $6.30 per share in a broker-assisted transaction tied to restricted stock unit vesting. After the sale, she directly beneficially owned 85,105 common shares. The filing explains the transaction was executed under a durable automatic sale instruction plan adopted on December 19, 2024, solely to cover withholding tax liabilities and did not represent a discretionary trade.
Karyopharm Therapeutics Inc. executive Sohanya Cheng, EVP & Chief Commercial Officer, received an award of 32,415 shares of common stock in the form of restricted stock units on January 31, 2026. The RSUs were granted at $0 per share under the company’s 2022 Equity Incentive Plan.
The RSUs convert into common stock on a one-for-one basis, with 50% vesting on January 31, 2027 and the remaining 50% vesting on January 31, 2028. Following this grant, Cheng beneficially owns 111,921 shares of Karyopharm common stock in direct ownership.
Karyopharm Therapeutics reported that its EVP & Chief Medical Officer, Reshma Rangwala, received an award of 32,415 restricted stock units (RSUs) of common stock on January 31, 2026 at a price of $0 per share. The RSUs were granted under the company’s 2022 Equity Incentive Plan and convert into common stock on a one-for-one basis. Half of the shares vest on January 31, 2027, with the remaining half vesting on January 31, 2028. Following this award, Rangwala beneficially owns 61,805 shares of Karyopharm common stock directly.
Karyopharm Therapeutics Inc. reported an equity compensation award to its EVP, CFO & Treasurer, Lori Macomber. She received 32,415 restricted stock units (RSUs) of Karyopharm common stock at a grant price of $0.
The RSUs convert into common stock on a one-for-one basis. They vest in two equal installments, with 50% vesting on January 31, 2027 and the remaining 50% on January 31, 2028. Following this grant, Macomber beneficially owns 86,731 shares of Karyopharm common stock.
Karyopharm Therapeutics Inc. executive Michael Mano, EVP, CLO & Secretary, received an equity award of 32,415 shares of common stock on January 31, 2026. The award was granted at a price of $0 per share under the company’s 2022 Equity Incentive Plan as restricted stock units.
The RSUs convert into common stock on a one-for-one basis and vest over time, with 50% of the shares vesting on January 31, 2027 and the remaining 50% vesting on January 31, 2028. Following this grant, Mano directly beneficially owns 97,490 shares of Karyopharm common stock.
Karyopharm Therapeutics Inc. executive vice president and chief development officer Stuart Poulton reported an award of 32,415 shares of common stock on January 31, 2026. These were granted as restricted stock units under the company’s 2022 Equity Incentive Plan at a price of $0 per share.
The RSUs convert into common stock on a one-for-one basis. Half of the award is scheduled to vest on January 31, 2027, and the remaining half on January 31, 2028. Following this grant, Poulton beneficially owns 99,807 shares of Karyopharm common stock in direct ownership.
Affinity Asset Advisors, LLC and Michael Cho report beneficial ownership of 1,713,092 shares of Karyopharm Therapeutics Inc. common stock, representing 8.6% of the outstanding class as of January 22, 2026. This total includes 1,573,517 shares issuable upon exercise of warrants.
The warrants are subject to a 9.99% beneficial ownership limitation, which caps how many shares can be acquired through exercise relative to Karyopharm’s outstanding stock. The ownership percentages are calculated using 19,883,800 shares of common stock, combining currently outstanding shares and the warrant shares counted for this filing.
Karyopharm Therapeutics’ Chief Accounting Officer Kristin Abate reported the vesting of performance-based restricted stock units and a small share sale. On January 27, 2026, 92 shares of common stock were acquired at $0.0 upon PSUs vesting tied to revenue and total shareholder return milestones.
On January 28, 2026, Abate sold 50 shares of common stock at $7.03 per share to cover withholding tax from the PSU vesting under a pre-established automatic sale plan, described as non-discretionary. After these transactions, she directly owned 22,622 shares of Karyopharm common stock.
Karyopharm Therapeutics Inc.'s Chief Accounting Officer, Kristin Abate, reported an automatic sale of company stock. On 01/21/2026, she sold 265 shares of common stock at $5.96 per share, leaving her with 22,580 shares held directly after the transaction.
The filing explains that this was a broker-assisted sale executed under a durable automatic sale instruction plan adopted on May 27, 2021. The sale was made solely to cover withholding tax liabilities arising from the vesting of restricted stock units and is described as not a discretionary trade by the reporting person.